Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

BACKGROUND: Triweekly capecitabine plus irinotecan (CAPIRI) was not a replacement for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the treatment of metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Recently, it has reported that mCAPIRI is well tolerated and...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Nobuaki, Hazama, Shoichi, Nagasaka, Takeshi, Tanioka, Hiroaki, Iwamoto, Yasuo, Negoro, Yuji, Yamauchi, Masami, Kobayashi, Michiya, Okuda, Hiroshi, Fujishima, Noriaki, Nishimura, Taku, Yamanaka, Naoki, Toyota, Kazuhiro, Mori, Yoshiko, Nakagami, Yuki, Shimokawa, Mototsugu, Nagano, Hiroaki, Okajima, Masazumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736909/
https://www.ncbi.nlm.nih.gov/pubmed/31144145
http://dx.doi.org/10.1007/s10147-019-01473-3

Ejemplares similares

Ejemplares similares